AstraZeneca (AZN) files Iran‑related disclosure in 20‑F annual report

Rhea-AI Filing Summary

AstraZeneca PLC submitted a notice that it has included disclosures required by Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act in its Annual Report on Form 20-F for the year ended December 31, 2025. The company states the disclosure appears under "Item 4.B Business Overview—Disclosures Under the Iran Threat Reduction and Syria Human Rights Act of 2012."

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge, CB2 0AA

United Kingdom

T: +44 (0) 20 3749 5000

astrazeneca.com

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

February 24, 2026

Re:            Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act

Ladies and Gentlemen,

Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that AstraZeneca PLC has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2025, which was filed with the Securities and Exchange Commission on February 24, 2026. The disclosure can be found under the heading “Item 4.B Business Overview—Disclosures Under the Iran Threat Reduction and Syria Human Rights Act of 2012” in the Annual Report on Form 20-F.

Respectfully submitted,

/s/ Matthew Bowden

Matthew Bowden

Company Secretary

AstraZeneca PLC

AstraZeneca PLC

Registered in England No. 2723534

Registered office: 1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge, CB2 0AA

United Kingdom

FAQ

What did AstraZeneca (AZN) disclose under the Iran Threat Reduction and Syria Human Rights Act?

AstraZeneca disclosed information pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act and Section 13(r) in its Form 20-F. The disclosure is located under Item 4.B Business Overview—Disclosures Under the Iran Threat Reduction and Syria Human Rights Act of 2012 in the 2025 report.

Where can investors find AstraZeneca's (AZN) disclosure related to Sections 219 and 13(r)?

Investors can find the disclosure in AstraZeneca's Annual Report on Form 20-F for the year ended December 31, 2025, specifically under the heading Item 4.B Business Overview—Disclosures Under the Iran Threat Reduction and Syria Human Rights Act of 2012.

When did AstraZeneca (AZN) file the notice about this disclosure with the SEC?

AstraZeneca submitted the notice to the U.S. Securities and Exchange Commission on February 24, 2026. The notice states the related disclosure appears in the Form 20-F for the year ended December 31, 2025.

Does the notice state where in the Form 20-F the Iran-related disclosure appears?

Yes. The notice specifies the disclosure appears under Item 4.B Business Overview—Disclosures Under the Iran Threat Reduction and Syria Human Rights Act of 2012 in the Annual Report on Form 20-F for the year ended December 31, 2025.

Who signed the SEC notice on behalf of AstraZeneca (AZN)?

The SEC notice was signed by Matthew Bowden, Company Secretary of AstraZeneca PLC. The letterhead shows the company's registered address at 1 Francis Crick Avenue, Cambridge Biomedical Campus.